N-(1-(Furan-2-yl)-3-oxo-3-((pyridin-3-ylmethyl)amino)prop-1-en-2-yl)benzamide | 324562-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1-(Furan-2-yl)-3-oxo-3-((pyridin-3-ylmethyl)amino)prop-1-en-2-yl)benzamide
• 英文别名: N-[(E)-1-(furan-2-yl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide
• CAS: 324562-01-8
• 化学式: C₂₀H₁₇N₃O₃
• 分子量: 347.4
• InChiKey: ANTQNDKESCDJPE-LDADJPATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  84.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Prokineticin 1 receptor agonists and their uses
  申请人：Université de Strasbourg

  公开号：EP2468279A1

  公开（公告）日：2012-06-27

  The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKR1 mediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impaired gastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadian rhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs.

  本发明公开了非肽类促激肽1受体激动剂及其在治疗PKR1介导的疾病方面的用途，特别是在治疗血管疾病、神经退行性疾病、胃肠道蠕动受损疾病、肥胖症、卡尔曼综合征、正常性腺功能减退症和昼夜节律紊乱方面的用途，以及在预防或限制药物毒性，特别是心脏毒性和神经毒性方面的用途。
• Use of prokineticin 1 receptor agonists to promote the differentiation of epicardin+ progenitor cells
  申请人：Université de Strasbourg

  公开号：EP2468280A1

  公开（公告）日：2012-06-27

  The present invention discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cells into cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cells into vasculogenic and/or glomerular cells in a subject affected with a renal disease.

  本发明公开了一种原激肽原受体-1激动剂，用于促进心脏疾病患者的心外膜+祖细胞分化为心肌细胞，和/或促进肾脏疾病患者的肾外膜+祖细胞分化为血管生成细胞和/或肾小球细胞。
• [EN] PROKINETICIN 1 RECEPTOR AGONISTS AND THEIR USES<br/>[FR] AGONISTES DE RÉCEPTEUR DE PROKINÉTICINE 1 ET LEURS UTILISATIONS
  申请人：UNIV STRASBOURG

  公开号：WO2012084999A1

  公开（公告）日：2012-06-28

  The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKRl mediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impaired gastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadian rhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs. The present invention also discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cells into cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cells into vasculogenic and/or glomerular cells in a subject affected with a renal disease. The present invention further discloses a prokineticin receptor-1 agonist for use for treating or preventing insulin resistance, in particular associated with type II diabetes.